Generics Bulletin - News And Expert Analysis On Generics And Biosimilars since 2003

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

The key advantages of the European centralized procedure, its usage by generics and biosimilars developers and the EU Pharmaceutical strategy and legislation were discussed at length in a recent webinar hosted by Medicines for Europe.

At its debut year-end financial earnings call, Organon spoke in further detail about the impending launch of Humira biosimilars, as well as its desire to continue growing its portfolio.

Zydus and Synthon’s entry into a high-value collaboration on palbociclib tablets is amped up with a paragraph IV certification, which may lead to a 180-day market exclusivity.